Marzena Olesinska
Overview
Explore the profile of Marzena Olesinska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
1457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Denton C, Kowal-Bielecka O, Proudman S, Olesinska M, Worm M, Papa N, et al.
Rheumatology (Oxford)
. 2025 Feb;
PMID: 39909490
Objectives: The primary objective was the safety of subcutaneous immunoglobulin, IgPro20 (Hizentra, CSL Behring) in adults with diffuse cutaneous systemic sclerosis (dcSSc). Secondary objectives included pharmacokinetics and relative bioavailability of...
2.
Wysocki T, Wajda A, Kmiolek T, Wronski J, Roszkowska M, Olesinska M, et al.
Clin Immunol
. 2024 Dec;
271():110414.
PMID: 39643026
The aim of this research was to prospectively evaluate the impact of NOX2 gene expression profile (including NCF1, NCF2 and NCF4 genes) in peripheral blood mononuclear cells (PBMCs) on immune...
3.
Haladyj E, Matusiewicz A, Wysocki T, Olesinska M
Reumatologia
. 2024 Oct;
62(4):266-273.
PMID: 39381730
Introduction: Antiphospholipid syndrome (APS) manifests with thrombosis and pregnancy losses and may significantly impair the health-related quality of life (HRQoL). So far, APS has been perceived as a less burdensome...
4.
Romanowska-Prochnicka K, Dziewit M, Lesiak A, Reich A, Olesinska M
Front Immunol
. 2024 Aug;
15:1456067.
PMID: 39104532
[This corrects the article DOI: 10.3389/fimmu.2024.1351675.].
5.
Romanowska-Prochnicka K, Dziewit M, Lesiak A, Reich A, Olesinska M
Front Immunol
. 2024 Jun;
15:1351675.
PMID: 38887288
Systemic sclerosis is a systemic connective tissue disease whose main pathophysiological mechanism is a progressive fibrosis of internal organs and skin leading to thickening and induration. Blood vessels may also...
6.
Miernik S, Matusiewicz A, Olesinska M
Biomedicines
. 2024 May;
12(5).
PMID: 38790948
Drug-induced myopathies are a common cause of muscle pain, and the range of drugs that can cause muscle side effects is constantly expanding. In this article, the authors comprehensively discuss...
7.
Chmielinska M, Felis-Giemza A, Olesinska M, Paradowska-Gorycka A, Szukiewicz D
Rheumatol Int
. 2024 May;
44(8):1487-1499.
PMID: 38743252
Background: A significant number of patients with axial spondyloarthritis (axSpA) do not respond to biological therapy. Therefore, we decided to investigate the specificity of this group of patients and, in...
8.
Paczwa K, Rerych M, Romanowska-Prochnicka K, Olesinska M, Rozycki R, Golebiewska J
J Clin Med
. 2024 Apr;
13(7).
PMID: 38610789
The comparison of retinal perfusion in the eyes of patients with systemic sclerosis (SSc) and in healthy controls using optical coherence tomography angiography (OCTA). The correlation between nailfold capillaroscopy results...
9.
Ornowska S, Wudarski M, Dziewiecka E, Olesinska M
Clin Rheumatol
. 2024 Mar;
43(5):1703-1709.
PMID: 38509242
Introduction: Mixed connective tissue disease (MCTD) is a rare systemic disease characterized by overlapping features of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), dermato-/polymyositis (DM/PM), and rheumatoid arthritis (RA). Naifold...
10.
Filipowicz G, Wajda A, Stypinska B, Kmiolek T, Felis-Giemza A, Stanczyk S, et al.
Int J Mol Sci
. 2023 Oct;
24(20).
PMID: 37895173
Mixed connective tissue disease (MCTD) is a very rare disorder that belongs in the rare and clinically multifactorial groups of diseases. The pathogenesis of MCTD is still unclear. The best...